The stock of Eton Pharmaceuticals approaches the all-time high again after record quarter!

Eton Pharmaceuticals specializes in the development of drugs for rare diseases. This year, several drugs have already been launched, including Increlex and Galzin. The latter is used for the treatment of Wilson's disease. Three new drugs are expected to be introduced in the coming months. On August 7, the company impressed with its Q2 numbers, achieving another record quarter with over 100% revenue growth. Management described the year 2025 as the most exciting year in the company’s history and now expects to reach the previously targeted annual...